The briefing
The PEMDA-HN trial reported final results evaluating danvatirsen in combination with pembrolizumab. Investigators from multiple cancer centers shared outcomes from the study in patients with cancer.
Original headline
HN Trial Reports Final Results on Danvatirsen Plus Pembrolizumab